Gyala Therapeutics Launches Phase I/IIa Clinical Trial of CAR-T Cell Therapy for Acute Leukemias Gyala Therapeutics has begun a Phase I/IIa clinical trial for its CAR-T cell therapy GYA01, targeting acute leukemias with few treatment options.

Gyala Therapeutics Launches Phase I/IIa Clinical Trial of CAR-T Cell Therapy for Acute Leukemias #Spain #Barcelona #CAR-T_therapy #Gyala_Therapeutics #GYA01

Gyala Therapeutics Launches Pioneering CAR-T Cell Therapy Clinical Trial for Acute Leukemias Gyala Therapeutics has commenced a clinical trial for its CAR-T cell therapy, GYA01, targeting acute leukemia with limited treatment options. The study aims to offer hope to patients facing these challenging conditions.

Gyala Therapeutics Launches Pioneering CAR-T Cell Therapy Clinical Trial for Acute Leukemias #Spain #Barcelona #CAR-T_therapy #Gyala_Therapeutics #GYA01

Gyala Therapeutics Launches Revolutionary CAR-T Therapy GYA01 for Treating Leukemias Gyala Therapeutics has announced a groundbreaking CAR-T therapy, GYA01, showing excellent preclinical results against challenging leukemias. This innovation marks a significant step in treating blood cancers effectively.

Gyala Therapeutics Launches Revolutionary CAR-T Therapy GYA01 for Treating Leukemias #Spain #Barcelona #Gyala_Therapeutics #CAR-T_Therapy #GYA01